Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

An Open-Label Phase 1a/1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etakafusp alfa (Primary) ; Pembrolizumab (Primary)
  • Indications Carcinoma; Head and neck cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Asher Biotherapeutics

Most Recent Events

  • 02 Jun 2026 Results presented at the 62nd Annual Meeting of the American Society of Clinical Oncology
  • 21 May 2026 Results published in the Media Release
  • 21 May 2026 According to Asher Biotherapeutics media release, the data from this study will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 - June 2, 2026 in Chicago.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top